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OBJECTIVE
To evaluate the efficacy and safety of basal insulin peglispro (BIL) versus insulin
glargine inpatientswith type2diabetes (hemoglobinA1c [HbA1c]£9% [75mmol/mol])
treated with basal insulin alone or with three or fewer oral antihyperglycemic
medications.
RESEARCH DESIGN AND METHODS
This 52-week, open-label, treat-to-target study randomized patients (mean HbA1c
7.42% [57.6 mmol/mol]) to BIL (n = 307) or glargine (n = 159). The primary end
point was change from baseline HbA1c to 26 weeks (0.4% [4.4 mmol/mol] non-
inferiority margin).
RESULTS
At 26 weeks, reduction in HbA1c was superior with BIL versus glargine (20.82%
[28.9 mmol/mol] vs. 20.29% [23.2 mmol/mol]; least squares mean difference
20.52%, 95%CI20.67 to20.38 [25.7mmol/mol, 95%CI27.3 to24.2; P< 0.001);
greater reduction in HbA1cwith BIL wasmaintained at 52weeks.More BIL patients
achieved HbA1c <7% (53 mmol/mol) at weeks 26 and 52 (P < 0.001). With BIL
versus glargine, nocturnal hypoglycemia rate was 60% lower, more patients
achieved HbA1c <7% (53 mmol/mol) without nocturnal hypoglycemia at 26 and
52 weeks (P < 0.001), and total hypoglycemia rates were lower at 52 weeks (P =
0.03). At weeks 26 and 52, glucose variability was lower (P < 0.01), basal insulin
dose was higher (P < 0.001), and triglycerides and aminotransferases were higher
with BIL versus glargine (P < 0.05). Liver fat content (LFC), assessed in a subset of
patients (n = 162), increased from baseline with BIL versus glargine (P < 0.001),
with stable levels between 26 and 52 weeks.
CONCLUSIONS
BIL provided superior glycemic control versus glargine, with reduced nocturnal
and total hypoglycemia, lower glucose variability, and increased triglycerides,
aminotransferases, and LFC.
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Many patients with type 2 diabetes fail
to achieve glycemic control with basal
insulin plus oral antihyperglycemicmed-
ications (OAMs) (1). Barriers to achiev-
ing optimal glycemic control include
fear of hypoglycemia and weight gain
(2). Hypoglycemia is a limiting factor in
titration of basal insulin to achieve
glycemic targets (3,4).
Basal insulin peglispro (BIL) is PEGylated
insulin lispro with a half-life of 2–3
days in patients with type 2 diabetes and
duration of action related to delayed in-
sulin absorption and reduced clearance
(5). In patients with type 1 diabetes
and healthy subjects, BIL has hepato-
preferential action compared with
insulin glargine, resulting from lesser
peripheral action rather than an accen-
tuated or enhanced effect on the liver
(6–8). This liver-to-peripheral tissue
activity distribution is more consis-
tent with the physiological action of
endogenous insulin secretion (9,10).
In a 12-week phase 2 study comparing
BIL with glargine in patients with type 2
diabetes previously treated with basal
insulin, BIL was associated with similar
glycemic control, reductions in nocturnal
hypoglycemia and weight, and higher tri-
glycerides and aminotransferases (11).
This 52-week phase 3 open-label study
compares the efficacy and safety of
switching to BIL in patients with type 2
diabetes previously treated with basal in-
sulin alone or in combination with up to
three OAMs.
RESEARCH DESIGN AND METHODS
This phase 3, open-label, multicenter,
multinational, randomized, controlled,
parallel-design trial (Supplementary
Fig. 1) was approved by local ethics re-
view boards and conducted in accor-
dance with Good Clinical Practice of
the International Conference on Harmo-
nisation guideline. All patients provided
written informed consent. An un-
blinded, independent data monitoring
committeemonitored patient safety. En-
rollment started in May 2012, and the
last patient completed in December
2013.
Data were analyzed according to the
predefined statistical analysis plan. To
minimize potential bias in this open-
label study, the sponsor study team, in-
cluding the physician overseeing global
conduct of the study and statistician,
remained blinded prior to primary
database lock at 26weeks. Investigators
and patients were aware of treatment
assignment.
Participants
Adults with type 2 diabetes (12) were
eligible if treated with basal insulin
(insulin glargine, insulin detemir, or
NPH insulin) alone or with three or
fewer OAMs for $90 days and had he-
moglobin A1c (HbA1c) #9% (75 mmol/mol)
(additional inclusion/exclusion criteria
in Supplementary Table 1). Investiga-
tors at 65 study centers in eight countries
participated (Supplementary Table 2).
Study Design and Treatment
After a 1-week prerandomization pe-
riod, including collection of baseline hy-
poglycemia data, randomization to BIL
or glargine (Lantus, Sanofi) occurred by
country with block size of six (2:1 ran-
domization), stratified on baseline HbA1c
(# or .8.0% [64 mmol/mol]), LDL cho-
lesterol (LDL-C) (, or $100 mg/dL),
and sulfonylurea/meglitinide use.
OAM doses were to remain stable ex-
cept in emergency situations or if
contraindications developed.
Bedtime dosing of study basal insulin
was initiated (Supplementary Table 3)
and adjusted according to a treat-to-
target algorithm (goal fasting blood
glucose [FBG] by self-monitored
blood glucose [SMBG] #100 mg/dL)
(Supplementary Table 3). Algorithm ad-
herence was mandatory up to week 26.
After week 26, basal insulin dosing was
determined by the investigator, and res-
cue therapy (prandial rapid-acting insu-
lin) was permitted for HbA1c $8.0%
(64 mmol/mol) or FBG $250 mg/dL for
3 days over 2 weeks. Lipid and hepatic
criteria for study insulin discontinuation
are listed in Supplementary Table 4.
Patients performed SMBG each
morning fasting, with two 6-point
SMBG profiles (fasting, prior to mid-
day/evening meals, bedtime, 0300 h,
and next day fasting) prior to prespeci-
fied visits, and whenever hypoglycemia
was suspected. Hypoglycemia was de-
fined as signs/symptoms of hypoglyce-
mia or measured SMBG #70 mg/dL.
Nocturnal hypoglycemia was an event
occurring between bedtime and waking.
Documented symptomatic hypoglyce-
mia was an event associated with signs/
symptoms of hypoglycemia andmeasured
SMBG #70 mg/dL. Severe hypoglycemia
was determined by the investigator as an
episode with a medical need for assis-
tance of another person to administer
carbohydrates, glucagon, or other resus-
citative actions.
Deaths and nonfatal cardiovascular
events (myocardial infarction, stroke,
and hospitalization for unstable angina)
were adjudicated by an independent
clinical end point committee. Adjust-
ments in lipid-lowering therapy were
prohibited from randomization to
week 12. In a patient subgroup, MRI
was performed to assess liver fat con-
tent (LFC) and abdominal visceral-to-
subcutaneous fat ratio (13). MRI sites
in the U.S., Puerto Rico, Germany, and
Greece underwent qualification pro-
cedures, including phantom scan-
ning. Study images were centrally
read by a vendor with MRI expertise in
multicenter trials (VirtualScopics, Inc.,
Rochester, NY).
Statistical Analyses
Analyses (SAS 9.1 or higher, Cary, NC)
were based on all randomized patients
who took at least one dose of study in-
sulin. The primary efficacy measure in
this 52-week study was noninferiority of
BIL to glargine for HbA1c change from 0 to
26 weeks (margin 0.4% [4.4 mmol/mol]).
For control of the overall type 1 error
at a = 0.05, a sequential gatekeeping
strategy (14) was used to adjust for
multiplicity for the primary and six
key secondary objectives. The six key
secondary objectives (in order) were
to demonstrate superiority of BIL ver-
sus glargine at/during 26 weeks of
treatment for nocturnal hypoglycemia
rate, percent patients with HbA1c,7%
(53 mmol/mol) without experiencing
nocturnal hypoglycemia, change in
HbA1c, percent patients with HbA1c
,7% (53 mmol/mol), total hypoglyce-
mia rate, and laboratory fasting serum
glucose (FSG). The gated objective was
met if all preceding objectives were
met, and the gated objective reached
statistical significance at a = 0.05.
A total of 426 randomized patients
provided 90% statistical power to dem-
onstrate noninferiority of BIL to glargine
(margin 0.4% [4.4 mmol/mol]) for
change in HbA1c from 0 to 26 weeks
with assumptions of no difference be-
tween treatment, SD of 1.1%, at two-
sided a-level 0.05, and 15% dropout
rate in 26 weeks.
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A mixed-model repeated-measures
model was used to analyze HbA1c, con-
tinuous glycemic variables, and weight.
HbA1c,7.0% (53 mmol/mol) and HbA1c
,7% (53 mmol/mol) without nocturnal
hypoglycemia (last observation carried
forward) were analyzed using logistic
regression. Hypoglycemia rates were
compared using negative binomial re-
gression with adjustment for treatment,
baseline sulfonylurea/meglitinide use,
and baseline hypoglycemia rate (15).
Between-group differences are pre-
sented as least squares mean (LSM) dif-
ference (BIL 2 glargine) and baseline
and end point values as LSM6 SE unless
otherwise indicated.
RESULTS
Patients (N = 466) were randomized to
BIL (n = 307) or glargine (n = 159). Pa-
tient disposition was similar between
groups (Supplementary Fig. 2). There
were no significant differences in inci-
dence of discontinuations at 26 or 52
weeks. Baseline characteristics, includ-
ing OAM use, were similar between
groups (Table 1). OAM treatment over-
all remained stable throughout the
study; 1.5% of patients had protocol
violations for OAM changes other than
safety reasons as allowed per protocol.
The primary objective, noninferiority
of BIL compared with glargine for HbA1c
change from 0 to 26 weeks, was achieved
with LSM difference of20.52% (95% CI
20.67 to 20.38) (25.7 mmol/mol
[95% CI 27.3 to 24.2]) indicating
statistical superiority of BIL compared
with glargine with multiplicity adjust-
ment (P, 0.001) (Fig. 1A). At 52 weeks,
change from baseline HbA1c (LSM)
for BIL- and glargine-treated pa-
tients was 20.67% (27.3 mmol/mol)
and 20.22% (22.5 mmol/mol), re-
spectively (P , 0.001) (Fig. 1A). More
BIL-treated patients achieved HbA1c
,7% (53 mmol/mol) at week 26 (72.5
vs. 52.2%, P , 0.001) and week 52
(63.9 vs. 45.9%, P , 0.001) (Fig. 1B). At
week 26, more BIL-treated patients
achieved HbA1c #6.5% (48 mmol/mol)
(50.3 vs. 28.7%, P , 0.001), HbA1c
,7% (53 mmol/mol) without experienc-
ing nocturnal hypoglycemia from 0–26
weeks (40.1 vs. 18.5%, P , 0.001), and
HbA1c #6.5% (48 mmol/mol) without
experiencing nocturnal hypoglycemia
from 0 to 26 weeks (28.1 vs. 8.9%, P ,
0.001); at week 52, more BIL-treated pa-
tients also achieved these HbA1c targets
(P , 0.001). Laboratory FSG was lower
for BIL versus glargine at weeks 26 and
52 (Table 2).
FBG from SMBG was similar between
BIL and glargine at weeks 26 (106.3 6
1.1 vs. 104.5 6 1.5 mg/dL) and 52
(110.6 6 1.2 vs. 107.5 6 1.7 mg/dL).
At weeks 26 and 52, six-point SMBG pro-
file daily mean glucose and midday pre-
meal, evening premeal, and bedtime
SMBG levels were lower with BIL
(Fig. 2A and Supplementary Fig. 3).
Between-day FBG variability (SD of
FBG in preceding 7 days) was lower
with BIL at weeks 26 (24.19 mg/dL,
P , 0.001) and 52 (23.20 mg/dL, P =
0.004), as was within-day variability
(SD of six-point SMBG) at weeks 26
(26.30 mg/dL, P , 0.001) and 52
(24.81 mg/dL, P = 0.001). Bedtime to
premorning meal excursion was re-
duced with BIL versus glargine at weeks
26 (218.22 mg/dL; P , 0.001) and 52
(219.16 mg/dL; P, 0.001), as was bed-
time to 0300 h excursion at weeks 26
(212.27 mg/dL, P = 0.003) and 52
(215.67 mg/dL, P , 0.001).
Total hypoglycemia relative rate for
BIL/glargine was 0.79 from 0 to 26
weeks (P = 0.05) and 0.77 from 0 to 52
weeks (P = 0.03) (Table 2). Total hypo-
glycemia incidence from 0 to 26 and 0 to
52 weeks was similar between treat-
ments. There were no differences in
rate or incidence of documented symp-
tomatic hypoglycemia (Table 2). Noctur-
nal hypoglycemia rate and incidence
and documented symptomatic noctur-
nal hypoglycemia rate and incidence
were lower for BIL than glargine from
weeks 0–26 and 0–52 (Table 2). The per-
centage of symptomatic hypoglycemia
episodes (BIL, 52%; glargine, 51%)
and the LSM glucose value associated
with symptomatic hypoglycemia events
Table 1—Baseline demographics and disease characteristics
Glargine BIL
n 159 307
Age (years), mean 6 SD 60.4 6 10.1 61.8 6 8.5
Men, n (%) 93 (58.5) 175 (57.0)
Race/ethnicity, n (%)
American Indian or Alaskan Native 0 (0.0) 2 (0.7)
Asian 2 (1.3) 4 (1.3)
Black or African American 9 (5.7) 17 (5.6)
Multiple 0 (0.0) 1 (0.3)
Native Hawaiian or other Pacific Islander 0 (0.0) 1 (0.3)
White 148 (93.1) 280 (91.8)
Hispanic or Latino 25 (15.7) 57 (18.6)
Weight (kg), mean 6 SD 91.8 6 18.5 92.2 6 17.1
BMI (kg/m2), mean 6 SD 31.9 6 5.0 32.1 6 5.0
Duration of diabetes (years), mean 6 SD 12.1 6 6.8 12.4 6 6.9
Baseline insulin use, n (%)
Insulin glargine 119 (74.8) 218 (71.0)
Insulin detemir 25 (15.7) 65 (21.2)
NPH insulin 15 (9.4) 24 (7.8)
OAMs at or prior to randomization, n (%)
Metformin 140 (88.1) 270 (88.5)
Sulfonylureas or meglitinides 74 (46.5) 144 (46.9)
Dipeptidyl peptidase-4 inhibitors 34 (21.4) 76 (24.9)
Thiazolidinediones 7 (4.4) 19 (6.2)
OAM use during treatment, n (%)
None 8 (5.0) 16 (5.2)
One 57 (35.8) 108 (35.4)
Two 83 (52.2) 141 (46.2)
Three 11 (6.9) 40 (13.1)
Patients using concomitant medications, n (%)
Lipid-lowering medications 109 (68.9) 213 (69.4)
Statins 103 (64.8) 195 (63.5)
Nonstatin lipid-lowering medications 24 (15.1) 63 (20.5)
HbA1c #8.0% (64 mmol/mol), n (%) 125 (78.6) 243 (79.2)
Hypertension, n (%) 133 (83.6) 264 (86.0)
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(BIL, 62.4 mg/dL; glargine, 61.3 mg/dL)
were not statistically significant between
groups (P = 0.071).
Cumulative total and nocturnal hypo-
glycemia events/100 patients over 52
weeks were lower for BIL than for glar-
gine (Fig. 2). Total hypoglycemia rate by
2-h intervals over 24 h from 0 to 52
weeks is displayed in Fig. 2D. BIL pa-
tients had overall stable total hypogly-
cemia rates over 24 h. In contrast,
glargine patients had higher rates from
0000 to 1000 h, with lower rates during
the day and the largest difference be-
tween groups occurring from 0400 to
0600 h. Through week 52, there were
two cases of severe hypoglycemia in
glargine-treated patients (Table 2).
Basal insulin dose (units/day and
units/kg/day) was higher for BIL pa-
tients beginning at week 2 through
week 52 (P , 0.001) (Fig. 1C). At week
26, basal insulin dose was higher with BIL
(53.2 units/day [0.57 units/kg/day]) vs.
glargine (47.0units/day [0.49units/kg/day];
P , 0.001). At week 52, basal dose
was essentially unchanged from week
26 for the BIL and glargine groups
(54.5 units/day [0.58 units/kg/day] vs.
47.0 units/day [0.49 units/kg/day], re-
spectively; P , 0.001). Investigator
adherence to the dosing algorithm
postbaseline up to week 26, when algo-
rithm compliance was required, was not
statistically significantly different be-
tween groups. Fromweek 26 to 52, eight
patients (BIL, n = 3 [1.1%]; glargine, n = 5
[3.5%]; P = 0.13) received bolus insulin
when rescue therapy was allowed per
the protocol based on glycemic parame-
ters. Weight increased with both
treatments and was not statistically sig-
nificantly different in BIL versus glargine-
treated patients at 26 or 52 weeks
(Fig. 1D).
With the prespecified gate-keeping
strategy for the primary and six key sec-
ondary objectives, superiority of BIL ver-
sus glargine at or during 26 weeks in
change in HbA1c, nocturnal hypoglycemia
rate, proportion of patients with HbA1c
,7% (53 mmol/mol), and proportion
achieving HbA1c ,7% (53 mmol/mol)
without nocturnal hypoglycemia was sta-
tistically significant with multiplicity ad-
justment. The fifth gated objective for
superiority of BIL versus glargine for total
hypoglycemia rate from baseline to 26
weeks did not meet the gate-keeping
test for multiplicity. The FSG for BIL was
lower versus glargine but did not meet
the gate-keeping test for multiplicity.
Treatment-emergent adverse events
were comparable between groups except
for more skin and subcutaneous tissue
disorders with BIL (Supplementary Table
5). Six (2.0%) BIL- and no glargine-treated
patients experienced prospectively
defined treatment-emergent adverse
events of injection site reactions of spe-
cial interest, including injection site
hypertrophy (n = 2), lipohypertrophy
(n = 2), injection site edema (n = 1), and
lipodystrophy (n = 1). Serious adverse
events were similar between treatments
Figure 1—HbA1c, percent of patients with HbA1c ,7%, basal insulin dose, and change in body weight over 52 weeks of treatment for BIL- and
glargine-treated patients. A: HbA1c (LSM 6 SE) over time. B: Percent of patients with HbA1c ,7.0% (53 mmol/mol) at baseline, 26 weeks, and 52
weeks. C: Basal insulin dose over time (LSM6 SE).D: Change in bodyweight over time (LSM6 SE). Closed circleswith solid line or black bar, BIL; open
circles with dashed line or white bar, insulin glargine. *P , 0.05 for between-treatment group comparisons.
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except that cardiac disorders and metab-
olism and nutrition disorders (hypoglyce-
mia and hypovolemia) occurred less
commonly with BIL (Supplementary
Table 5). Treatment-emergent anti-BIL
antibody responseswere similar between
groups (Table 2).
Adjudicated major adverse cardiac
events (MACE), including nonfatal
myocardial infarction, nonfatal stroke,
and cardiovascular death, were similar
between BIL and glargine: 2.3% vs.
4.4%, hazard ratio 0.5 (95% CI 0.18–1.43),
P = 0.20. There were no cases of
unstable angina with hospitalization;
thus, MACE+ results were equivalent to
MACE. Six deaths, three (1.0%) with BIL
(cardiac death, cardiac arrest, and pul-
monary hypertension) and three (1.9%)
with glargine (multiorgan failure,
myocardial infarction, and cardiac ar-
rhythmia) occurred. There were no dif-
ferences in heart rate or systolic or
diastolic blood pressure (Table 2).
Triglycerides increased from 0 to 4
weeks and remained overall stable
thereafter during BIL treatment, with
treatment differences through week
52 (LSM difference [BIL 2 glargine]
15 mg/dL, P = 0.026) (Table 2 and
Supplementary Fig. 4A). At study end
point, after transition off BIL, triglycer-
ides returned to baseline levels in the BIL
group and were lower than with glargine
(Supplementary Fig. 4A). One patient in
each treatment groupmetdiscontinuation
criteria of triglyceride level.600 mg/dL.
HDL cholesterol (HDL-C) decreased
from 0 to 4weeks with BIL and remained
Table 2—Treatment outcomes at baseline and after 26 and 52 weeks of treatment
Outcome
Baseline* 26 weeks 52 weeks
Glargine
(n = 159)
BIL
(n = 307)
Glargine
(n = 159)
BIL
(n = 307) P**
Glargine
(n = 159)
BIL
(n = 307) P**
HbA1c, %† 7.41 6 0.06 7.43 6 0.05 7.13 6 0.06 6.60 6 0.04 ,0.001 7.20 6 0.06 6.75 6 0.05 ,0.001
Change from baseline d d 20.29 6 0.06 20.82 6 0.04 20.22 6 0.06 20.67 6 0.05
LSM difference (95% CI) d d 20.52 (20.67 to 20.38) 20.44 (20.60 to 20.29)
HbA1c, mmol/mol† 57.5 6 0.7 57.7 6 0.5 54.4 6 0.7 48.7 6 0.5 ,0.001 55.1 6 0.7 50.3 6 0.5 ,0.001
Change from baseline d d 23.2 6 0.7 28.9 6 0.5 22.5 6 0.7 27.3 6 0.5
LSM difference (95% CI) d d 25.7 (27.3 to 24.2) 24.9 (26.5 to 23.2)
FSG, mg/dL† 128 6 3 135 6 2 120 6 3 104 6 2 ,0.001 116 6 3 108 6 2 0.02
Total hypoglycemia rate‡| 1.40 6 0.30 1.08 6 0.16 1.98 6 0.19 1.55 6 0.13 0.05 1.62 6 0.15 1.24 6 0.10 0.03
Total hypoglycemia incidence§ 30 (18.9) 51 (16.8) 128 (80.5) 232 (76.3) 0.35 132 (83.0) 244 (80.3) 0.54
Nocturnal hypoglycemia rate‡| 0.62 6 0.16 0.53 6 0.12 1.04 6 0.15 0.43 6 0.06 ,0.001 0.88 6 0.14 0.35 6 0.06 ,0.001
Nocturnal hypoglycemia
incidence§ 18 (11.3) 25 (8.2) 99 (62.3) 140 (46.1) 0.001 107 (67.3) 153 (50.3) ,0.001
Documented symptomatic
hypoglycemia rate‡| 0.51 6 0.15 0.58 6 0.12 0.90 6 0.15 0.78 6 0.10 0.47 0.77 6 0.12 0.60 6 0.07 0.21
Documented symptomatic
hypoglycemia incidence§ 13 (8.2) 29 (9.5) 88 (55.3) 160 (52.6) 0.549 98 (61.6) 176 (57.9) 0.411
Documented symptomatic
nocturnal hypoglycemia rate‡| 0.25 6 0.11 0.27 6 0.09 1.17 6 0.57 0.38 6 0.19 ,0.001 0.80 6 0.30 0.23 6 0.09 ,0.001
Documented symptomatic
nocturnal hypoglycemia
incidence§ 7 (4.4) 13 (4.3) 64 (40.3) 86 (28.3) 0.007 71 (44.7) 98 (32.2) 0.007
Severe hypoglycemia incidence§ 0 0 1 (0.6) 0 (0.0) d 2 (1.3) 0 (0.0) 0.12
ALT (IU/L)† 25.8 6 1.1 26.3 6 0.8 26.6 6 1.1 35.9 6 0.8 ,0.001 26.4 6 1.1 34.3 6 0.8 ,0.001
AST (IU/L)† 22.9 6 0.7 23.3 6 0.5 23.3 6 0.8 28.7 6 0.5 ,0.001 23.5 6 0.8 27.7 6 0.6 ,0.001
LDL-C (mg/dL)† 95.6 6 2.9 97.2 6 2.1 100.8 6 2.0 96.2 6 1.4 0.06 99.6 6 2.0 92.8 6 1.5 0.007
HDL-C (mg/dL)† 46.4 6 1.0 48.0 6 0.7 47.3 6 0.5 45.7 6 0.4 0.009 45.4 6 0.5 43.9 6 0.4 0.02
Non-HDL-C (mg/dL)† 124.4 6 3.2 126.5 6 2.3 129.0 6 2.2 129.2 6 1.6 0.927 130.1 6 2.3 127.1 6 1.6 0.28
Triglycerides (mg/dL)† 144 6 6 149 6 4 143 6 5 169 6 4 ,0.001 158 6 6 174 6 4 0.03
Systolic blood pressure (mmHg)† 132 6 1 132 6 1 135 6 1 134 6 1 0.309 133 6 1 133 6 1 0.930
Diastolic blood pressure (mmHg)† 76 6 1 77 6 1 78 6 1 78 6 0 0.899 77 6 1 78 6 0 0.601
Treatment-emergent
antibody response¶ d d 9 (6.3) 33 (11.7) 0.089 13 (9.7) 27 (10.4) 0.85
LFC (%)†# 10.0 6 1.1 10.4 6 0.8 9.1 6 0.7 15.1 6 0.5 ,0.001 9.6 6 0.8 14.9 6 0.5 ,0.001
Abdominal visceral-to-
subcutaneous fat ratio#†† 0.72 0.68 0.69 0.72 0.001 0.68 0.74 ,0.001
n reflects maximal sample size. *No between-treatment differences (P. 0.05) in any baseline parameter. †LSM6 SE. ‡Group mean6 SE. §Number
of patients (%). |For hypoglycemia rate data, values shown are events/patients/30 days for baseline to week 26 and baseline to week 52.
¶Treatment-emergent anti-BIL antibody response is defined as change from baseline to postbaseline in the anti-BIL antibody level either 1) from
undetectable to detectable and the postbaseline value $1% + cut point or 2) from detectable to the value with a relative change
([postbaseline2 baseline]/baseline) $30% and absolute change$1%. #N = 52 for glargine; N = 110 for BIL. **Between-treatment differences.
††LSM.
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lower than baseline through week 52, re-
sulting in lower HDL-C (,2 mg/dL) with
BIL versus glargine at week 52 (Table 2,
Supplementary Fig. 4B). At study end
point, after transition off treatment,
HDL-Cwas higher with BIL versus glargine
(Supplementary Fig. 4B). There were no
treatment differences in LDL-C at week
26, and LDL-Cwas lowerwithBIL atweeks
4 and 52 (Table 2 and Supplementary Fig.
4C). There were no differences in total
cholesterol between groups during treat-
ment (Supplementary Fig. 4D) or non-
HDL-C (Table 2). Therewere no significant
differences in the use of lipid-lowering
medication or changes to lipid-lowering
medications between the treatment
groups.
Alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) in-
creased from baseline with BIL and de-
creased toward baseline after transition
off BIL, with treatment differences at all
time points (Table 2, Supplementary Fig.
5). Mean ALT and AST remained within/
slightly above reference ranges at all
times. Seven (2.3%) BIL- and no glargine-
treated patients experienced ALT three
or more times the upper limit of normal
(ULN). All seven patients had a reduc-
tion in ALT less than three times ULN
during the study, with four patients con-
tinuing treatment and three patients dis-
continuing BIL and completing study
visits. No patients in either group
had bilirubin two or more times ULN
postbaseline.
A patient subset participated in the
MRI addendum (n = 110 BIL, n = 52 glar-
gine). Baseline characteristics, change in
HbA1c, and liver/lipid laboratory results
in MRI addendum patients were consis-
tent with overall study results. Baseline
LFC (10%) was similar between groups
(Table 2). With BIL, LFC increased from
0 to 26 weeks and remained stable at
week 52. LFC did not change signifi-
cantly from baseline with glargine (Ta-
ble 2). LFC change from baseline was
higher with BIL versus glargine at weeks
26 and 52 (LSM difference 6.0% and
5.3%, respectively; P , 0.001). At 52
weeks, 10 (10.9%) BIL patients versus 1
(2.3%) glargine patient had an absolute
increase from baseline of $10% in LFC
(P = 0.103). Change from baseline of the
abdominal visceral-to-subcutaneous fat
ratio was higher with BIL versus glargine
at weeks 26 and 52 (LSM difference 0.04
and 0.06, respectively; P , 0.001)
(Table 2).
CONCLUSIONS
This is one of the first direct compari-
sons of two basal insulins in which
superiority in glycemic control was dem-
onstrated in a treat-to-target trial. In pa-
tients with type 2 diabetes previously
treated with basal insulin, switching to
Figure 2—SMBG and hypoglycemia for BIL- and glargine-treated patients. A: Six-point SMBG profile at baseline and 52 weeks. Premorning, fasting
(premorning meal); Pre-midday, pre-midday meal; Pre-evening, pre-evening meal. Data are LSM 6 SE. *P , 0.05 for between-treatment group
comparisons. B: Cumulative total hypoglycemia events/100 patients over time during 52 weeks of treatment. C: Cumulative nocturnal hypoglycemia
events/100 patients over time during 52 weeks of treatment. For both B and C, “lines” are continuous data points indicating rates of hypoglycemia
throughout 52 weeks of treatment.D: Total hypoglycemia by 2-h intervals (0–52 weeks). Data are group mean. GL, insulin glargine. The P value is for
between-treatment group comparisons.
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BIL compared with glargine resulted in a
clinically significant 0.5% (5.7 mmol/mol)
greater HbA1c reduction at 26 weeks
(6.6 vs. 7.1% [48.7 vs. 54.4 mmol/mol]).
Greater HbA1c reduction with BIL was
maintained at 52 weeks. In addition,
more BIL-treated patients reached
target HbA1c ,7.0% (53 mmol/mol)
and #6.5% (48 mmol/mol). Despite
greater HbA1c reduction, BIL-treated
patients experienced statistically and
clinically significant reductions in
nocturnal hypoglycemia.
The superior HbA1c reduction achieved
with BIL is noteworthy, since noninferior-
ity has usually been observed in basal in-
sulin treat-to-target trials (16–18). The
FSG levels in glargine-treated patients
were well within ranges reported in
many treat-to-target trials, whereas BIL-
treated patients had greater reduction in
FSG compared with glargine (19–21). Not
only was HbA1c efficacy in BIL-treated pa-
tients superior to glargine-treated pa-
tients, but the levels achieved were well
below those reported in many major in-
sulin clinical trials (16,18,21,22). The
HbA1c levels with BIL treatment were
slightly higher than those achieved
in the intensive arm of Action to Con-
trol Cardiovascular Risk in Diabetes
(ACCORD), in which multiple thera-
pies, including bolus insulin, were al-
lowed and the median HbA1c was 6.4%
(46 mmol/mol) (23).
Improved glycemic control was
achieved without increased rates of to-
tal or nocturnal hypoglycemia, impor-
tant limiting factors in titrating basal
insulin to achieve glycemic targets. Noc-
turnal hypoglycemia was consistently
lower in BIL-treated patients, with a clin-
ically relevant 60% rate reduction versus
glargine. Total hypoglycemia was also
reduced over 52 weeks, and more pa-
tients reached HbA1c,7% (53 mmol/mol)
without experiencing nocturnal hy-
poglycemia over 26 and 52 weeks. Re-
duced nocturnal hypoglycemia with BIL
was also seen in insulin-naı¨ve patients
with type 2 diabetes (24) and in phase
2 BIL studies (11,25) and may reflect its
longer duration of action and lower
peak-to-trough ratio, as well as reduced
glucose variability versus glargine, with
potentially more stable and predictable
metabolic control (26).
Basal insulin dose was higher in BIL-
versus glargine-treated patients (;13%
and ;16% higher at weeks 26 and 52,
respectively). With modeling of HbA1c
and basal insulin dose, HbA1c reduction
per 10 units of basal insulin from 0 to 26
weeks was 0.36% (3.9mmol/mol) for BIL
and 0.30% (3.3 mmol/mol) for glargine,
suggesting that BIL was at least as po-
tent as glargine on a per unit basis.
These results suggest that BIL may be
titrated effectively to reach glycemic
targets due to lower nocturnal hypogly-
cemia rates with less glucose variability
and smaller overnight glucose excur-
sions. In addition, potential basal
insulin coverage throughout the day
with greater reduction in afternoon/
evening SMBG levels, when the effects
of glargine may be waning, could have
also contributed to the greater improve-
ment in glycemic control with BIL com-
pared with glargine in a treat-to-target
setting. Although BIL had greater effects
on HbA1c and other glycemic measures
and patients had higher basal insulin
doses, weight was not statistically signif-
icantly different with BIL versus glargine
at 26 or 52 weeks. This contrasts with a
phase 2 BIL study in patients with type 2
diabetes in which weight loss and similar
HbA1c was seen, possibly reflecting
smaller sample size and 12-week dura-
tion, which may have limited titration
to optimal basal insulin dose.
Increased mean aminotransferases,
within or slightly above reference
ranges, were seen with BIL. ALT at or
above three times ULN occurred in
2.3% of BIL-treated patients, but no
cases were associated with increases in
bilirubin at or above two times ULN.
Hence, no patients met criteria for Hy’s
law, a predictor of future risk of severe
drug-induced liver injury (27), consistent
with other BIL studies (11,24,25).
In theMRI subset, LFC and visceral-to-
subcutaneous fat ratio increased in BIL-
but not glargine-treated patients at 26
weeks and remained stable in both
groups at 52 weeks. This contrasts with
the IMAGINE 2 study findings in insulin-
na ı¨ve patients with type 2 diabetes,
where BIL-treated patients had no sig-
nificant change in LFC, but glargine-
treated patients had a reduction in LFC
from 13% at baseline to 10% at 52weeks
(24). In the insulin-na¨ıve study, the visceral-
to-subcutaneous fat ratio was similar
with BIL and glargine over 52 weeks.
Prior studies in insulin-naı¨ve patients
with type 2 diabetes have shown de-
creases in hepatic steatosis with 3–7
months of treatment with currently
available basal and premixed insulins
(28,29).
Conventional insulins may decrease
LFC in insulin-na ı¨ve patients with
type 2 diabetes by decreasing surplus
fatty acid delivery to the liver by increas-
ing fat delivery to the peripheral tissues
through increased lipoprotein lipase ac-
tivity and suppression of lipolysis in the
adipose tissue. An animal model has
recently demonstrated that hepatic
triglyceride synthesis is primarily depen-
dent on fatty acid delivery and indepen-
dent of hepatic insulin action or changes
in hepatic insulin signaling (30).
Baseline LFC (10%) in the current
study of patients previously treated
with basal insulin was similar to the re-
duced LFC level seen after 26 and 52
weeks in the glargine armof the IMAGINE
2 insulin-naı¨ve type 2 diabetes study
(24). In the current study, baseline LFC
may have already been decreased due to
prior treatment with conventional basal
insulins, primarily glargine; thus, glargine
treatment during the study had no fur-
ther effect on LFC. In contrast, switching
from a conventional basal insulin to BIL,
with limited peripheral access, may have
led to reduced suppression of peripheral
lipolysis and relatively higher fatty acid
delivery to the liver and increased LFC,
which remained stable through 52
weeks. Further research will help to un-
derstand the underlying mechanisms
and clinical consequences of these LFC
differences with BIL in patients previ-
ously treated with conventional basal
insulins.
Increased triglycerides with BIL re-
mained stable through 52weeks and de-
creased after stopping BIL, consistent
with other BIL studies in patients with
type 1 diabetes or type 2 diabetes pre-
viously treated with insulin (11,25). In
insulin-na¨ıve patients with type 2 diabe-
tes, triglyceride levels were essentially
unchanged with BIL and decreased
with glargine over 26 weeks of treat-
ment (24). Insulin glargine and other
conventional insulins have been associ-
ated with a reduction in triglyceride lev-
els (31–33). Increased triglycerides in
the current study were accompanied
by a ,2 mg/dL decrease in HDL, a de-
crease in LDL-C at week 52, and no dif-
ferences in non-HDL-C with BIL versus
glargine. As discussed above, we hy-
pothesize that the reduced peripheral
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action of BIL may increase relative fatty
acid delivery to the liver and, hence, in-
crease hepatic triglyceride reesterifica-
tion and VLDL secretion. Nonalcoholic
fatty liver disease and visceral adiposity
have been associated with cardiovascu-
lar risk factors (34). In BIL phase 3 type 2
diabetes studies, including IMAGINE 5,
there were no significant differences in
blood pressure between BIL and glar-
gine (24,35). In the BIL phase 2 and 3
program, there were no significant dif-
ferences in incidence rates of MACE+,
MACE, or all-cause death between BIL
and comparator (36).
Potential study limitations include
the open-label design, which may in-
crease risk of bias. Of note, the treat-
to-target SMBG FBG levels and dosing
algorithm adherence were not signifi-
cantly different in the BIL and glargine
groups. The BIL phase 3 program in-
cludes three double-blind studies in-
cluding IMAGINE 2 (24). Although this
global study involved eight countries,
the study population was primarily
white. The study patients overall had
reasonably controlled diabetes at base-
line given the eligibility criteria of HbA1c
#9% for safety reasons, as these pa-
tients were to continue a basal insulin
regimen with glargine or switch to new
therapy with BIL. The BIL phase 3 clinical
program includes patients with higher
baseline HbA1c levels (such as the
IMAGINE 2 study) as well as patients being
treated with other diabetes regimens.
This 52-week, treat-to-target study in
patients with type 2 diabetes previously
treated with basal insulin demonstrates
that switching to BIL provides superior
glycemic efficacy with clinically signifi-
cant reductions in HbA1c with lower
risk of nocturnal and total hypoglycemia
and lower glucose variability. Increases
were seen in aminotransferases, triglyc-
erides, and LFC in comparison with
glargine. The conversion from a conven-
tionally acting basal insulin to BIL, a
hepatopreferential insulin with reduced
peripheral action, may account for
these findings.
NOTE ADDED IN PROOF
Since this article was accepted for publica-
tion, Eli Lilly and Company has announced
plans to cease development of basal insu-
lin peglispro (https://investor.lilly.com/
releasedetail.cfm?ReleaseID=945541).
This decision is based on unresolved
questions regarding changes in liver fat
that developed during the late stages of
drug testing.
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